Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 23: 1888-1892, 1977;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szasz, G.
Right arrow Articles by Gruber, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szasz, G.
Right arrow Articles by Gruber, W.

Clinical Chemistry, Vol 23, 1888-1892, Copyright © 1977 by American Association for Clinical Chemistry

Creatine kinase in serum: 3. Further study of adenylate kinase inhibitors

G Szasz, W Gerhardt and W Gruber

In search of an appropriate inhibitor to suppress the interference of adenylate kinase with the creatine kinase assay, we found that the combination diadenosine pentaphosphate (10 mumol/liter) and AMP (5 mmol/liter) is a better inhibitor than is fluoride (25 mmol/liter). The latter inhibits adenylate kinase uncompetitively and weakly (Ki = 2.5 mmol/liter), and must be incorporated in the starting reagent, and at 30 degrees C it becoms fully effective only after a lag phase of 6 min. In this concentration, fluoride inhibits adenylate kinase from erythrocytes, muscle, liver or platelets by 94, 92, 88, and 87%, respectively, and creatine kinase by 8%. Bromide and chloride also inhibit creatine kinase. Attempts to replace AMP by a specific inhibitor of liver adenylate kinase failed. Homologs of diadenosine pentaphosphate with either fewer or more phosphoryl groups in the polyphosphate bridge inhibited even more weakly than did the pentaphosphate. Platelets can significantly contribute to adenylate kinase activity in serum. The inhibitor combination inhibited adenylate kinase from platelets by 90%.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. Rej
They Use Enzymes for Everything!
Clin. Chem., June 1, 1998; 44(6): 1149 - 1153.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
D. M. Nguyen, B. M. Gilfix, F. Dennis, D. Blank, D. A. Latter, P. L. Ergina, J. E. Morin, and B. de Varennes
Impact of Transfusion of Mediastinal Shed Blood on Serum Levels of Cardiac Enzymes
Ann. Thorac. Surg., July 1, 1996; 62(1): 109 - 114.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1977 by the American Association for Clinical Chemistry.